It seems pretty rare for companies to actively seek buyouts just to capture some discount on the present value of royalties. It's not as common as investors would like anyway.
It's also quite possible FRX looked at the Biolinerx project as well and must have passed. You'd think if it was actively shopped it would have made it's way to FRX.
If I thought that FRX would buy them out at $4-$5 even though I generally don't buy short term I would be a big buyer :-).
I took a pass on the company after hearing the call (even though I didn't listen real closely). I didn't like the direction they were heading. I agree with mcbio and Peter about repartnering being the best strategy on this compound. In general I don't like the idea of burning all one's cash and monetizing an only source of revenue to gamble and try to bring one drug to market especially as it seems the compound has more risk then I thought (its no ERT ;-)).
I was looking and the ownership data and management doesn't own much. I believe about half the shares were institutional one notable Royce (a big value player). I wouldn't be surprised to see some activist type push for a sale its surely got to be worth considerably more then its trading for today (people like me are probably discounting mgm decision(s) very heavily).
News 
Market Data 
Discover 
